Multimodal imaging in the characterization of tumors to assess tumor aggressiveness, diagnostic work-up and treatment response evaluation in prostate cancer, cervical cancer, breast cancer, sarcomas, spinal metastases, neuroendocrine tumors, GISTs, colorectal cancers, liver malignancies, multiple myeloma and lymphoma
Characterization of vascular inflammation inclusive vulnerability in atherosclerosis, treatment selection and treatment response evaluation using PET, MRI and US
Detection and treatment response evaluation in inflammatory and fibrosing diseases using different imaging modalities and PET tracers
Characterize pituritary microadenomas, remnant adenomas following surgery and hypophysitis by the use of different MRI and PET techniques
Radionuclide therapies for treatment of non-Hodgkin lymphoma, neuroendocrine tumors (NET) and Selective Internal Radiation Therapy (SIRT)
Development and testing of novel radionuclide therapies with emphasis on alpha-emitters
Molecular imaging and quantification of neurological diseases
Ultrasound-guided percutaneous ethanol injection treatment in patients with metastatic lymph nodes from thyroid carcinoma
Development of new biomarkers using radiomics and artificial intelligence (AI) for the characterization of diseases
Thunold S, Hernes E, Farooqi S, Öjlert ÅK, Francis RJ, Nowak AK, Szejniuk WM, Nielsen SS, Cedres S, Perdigo MS, Sørensen JB, Meltzer C, Mikalsen LTG, Helland Å, Malinen E, Haakensen VD(2024) Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine Eur J Nucl Med Mol Imaging(in press) DOI 10.1007/s00259-024-06853-0, PubMed 39133306
Andel PM, Aamodt AH, Gleditsch J, Melin E, Revheim MER, Steine K, Atar D(2024) Elective direct current cardioversion of atrial fibrillation - silent brain infarction and health related quality of life Cardiology(in press) DOI 10.1159/000540007, PubMed 39025051
Tulipan A, Kratochwil C, Lilleby J, Lilleby W(2024) A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancer Urol Case Rep, 54, 102752 DOI 10.1016/j.eucr.2024.102752, PubMed 38779691